
Shattuck Labs, Inc. ($STTK) announced an update on their ongoing clinical study. Study Overview: Shattuck Labs, Inc. (STTK) updated its first-in-human Phase 1 study of SL-325 in healthy volunteers, which
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| STTK | Shattuck Labs | 4.59 | 2.58 | 128.36% |
| Name | Price | % Change | |
|---|---|---|---|
| $4.59 | +128.36% |

Shattuck Labs, Inc. ($STTK) announced an update on their ongoing clinical study. Study Overview: Shattuck Labs, Inc. (STTK) updated its first-in-human Phase 1 study of SL-325 in healthy volunteers, which

Shattuck Labs, Inc. ($STTK) announced an update on their ongoing clinical study. Study Overview: Shattuck Labs, Inc. is preparing a Phase 2 study titled A Phase 2 Randomized, Double-blind, Placebo-controlled

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Shattuck Labs and keeping the price target at $14.00. Joseph Pantginis has given his Buy rating due to a

“We are very excited to begin Phase 2 clinical development with SL-325 in both Crohn’s disease and hidradenitis suppurativa. We believe these two studies will allow direct comparisons with the

UBS initiated coverage of Shattuck Labs (STTK) with a Buy rating and $17 price target The firm believes the company’s lead asset, SL-325, may offer a “meaningful advantage” over first-generation

Wedbush analyst David Nierengarten raised the firm’s price target on Shattuck Labs (STTK) to $14 from $11 and keeps an Outperform rating on the shares. The firm notes the company

Needham analyst Joseph Stringer raised the firm’s price target on Shattuck Labs (STTK) to $19 from $17 and keeps a Buy rating on the shares after the company announced its

Shattuck Labs (STTK) announced its plans to evaluate SL-325 in a Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa. RECEPTIVE-HS1 Phase 2 clinical trial in patients

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Shattuck Labs, retaining the price target of $14.00. Joseph Pantginis has given his Buy rating due to a combination

After Merck (MRK) presented Phase 2b data for tulisokibart in moderate-to-severe hidradenitis suppurativa at the EADV Congress and reported that it met the primary endpoint and will be advancing into
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Oct 20, 2026 | ||||
| buy | Initiated | Oct 11, 2026 | ||||
| buy | Assigned | Oct 2, 2026 | ||||
| buy | Reiterated | Oct 2, 2026 | ||||
| buy | Initiated | Aug 24, 2026 | ||||
| buy | Reiterated | Aug 12, 2026 | ||||
| buy | Reiterated | Aug 12, 2026 | ||||
| buy | Reiterated | May 7, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 16, 2027TBA | $474.59M | $-0.14 | $122.00K | 0.10 | -9.18 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.